Group 1 - Tsugami Machine Tool China (01651) saw a rise of over 5.4% due to increased demand for high-precision machine tools in emerging sectors like new energy vehicles and artificial intelligence as China's economy gradually recovers [1] - Black Sesame Intelligence (02533) increased by over 2.2% after announcing that its flagship product, the Huashan A1000 automotive-grade high-performance driving assistance chip, has been successfully integrated into Desay SV's new low-speed unmanned vehicle brand "Chuanxing Zhiyuan" S6 series [1] - Zai Xin Bio-B (02509) rose over 5.8% after receiving clinical trial approval for its self-developed long-acting dual antibody QX027N injection, intended for the treatment of asthma and atopic dermatitis [1] - CanSino Biologics (06185) increased nearly 5% as it announced the initiation of Phase I clinical trials for its inhaled tuberculosis vaccine in Indonesia [1] Group 2 - Kingsray Biotechnology (01548) rebounded over 4.48% following the financial performance disclosure of its joint venture Legend Biotech for the third quarter ending September 30, 2025 [2] - Fuhong Hanlin (02696) rose over 5.2% after its PD-1 antibody drug, Surufilumab injection, was proposed for breakthrough therapy designation for use in combination with chemotherapy for gastric cancer [2] - Yidu International Holdings (00259) increased over 6% amid uncertainty regarding the impact of an undisclosed event on its financial statements for the year ending March 31, 2025 [2] Group 3 - Reshaping Energy (02570) surged nearly 60%, with a rise of 55.03%, following announcements from the National Energy Administration encouraging the use of green hydrogen in coal chemical projects and plans to promote over 2,000 hydrogen vehicles in Shandong Province [3] - Laika Pharmaceuticals-B (02105) saw a reverse increase of over 10.3% after granting Qilu Pharmaceutical exclusive rights for research, development, and commercialization of the breast cancer candidate drug LAE002 (afuresertib) in China [3] Group 4 - WMCH GLOBAL (08208) resumed trading with a rise of over 50%, increasing by 57.45% after announcing the sale of approximately 384 million shares, representing about 53.297% of its issued share capital [4] Group 5 - U.S. stock market opened lower, with the Nasdaq dropping 2.04%, as major tech stocks like Nvidia, AMD, and Tesla saw declines [5] - Tencent reached an agreement with Apple regarding payment processing for WeChat mini-games, potentially opening new revenue streams for Apple [5] - Mangoceuticals (MGRX.US) plummeted 32.39% after announcing partnerships with Eli Lilly and Novo Nordisk to provide users with weight loss medications [6] - Fannie Mae (FNMA.US) fell 9.82%, with a two-day cumulative drop of 20%, amid investigations into the actions of the Federal Housing Finance Agency director [6] - Disney (DIS.US) dropped 7.75% despite strong performance in streaming and theme parks, as upcoming major film releases are expected to impact first-quarter performance [6]

Core Viewpoint - 康希诺生物's stock rose over 5%, reaching HKD 46.38, with a trading volume of HKD 16.1181 million, following the announcement of the initiation of Phase I clinical trials for its inhaled tuberculosis vaccine in Indonesia [1] Group 1: Clinical Development - 康希诺生物 has officially launched Phase I clinical trials for its inhaled tuberculosis vaccine (5-type adenovirus vector) in Indonesia, with the first subject enrolled [1] - The Phase I trial aims to explore the safety and immunogenicity of a single dose of the inhaled tuberculosis booster vaccine in adults aged 18 to 49 [1] Group 2: Financial Performance - 瑞银 has adjusted 康希诺生物's revenue forecasts for 2026 and 2027, increasing the 2026 forecast by 22% and decreasing the 2027 forecast by 9% [1] - 康希诺生物's management reported that the MCV4 vaccine generated revenue of RMB 662 million in the first three quarters of this year, representing a year-on-year growth of approximately 28%, attributed to an expanded age group and ongoing channel penetration [1] - The MCV4 vaccine began exporting to Indonesia in the third quarter, with estimated sales in the millions for this year [1] - The PCV13i vaccine, launched mid-year, has entered approximately 12 provinces, with management aiming to cover half of the provinces by year-end and expand to other markets next year [1]

人民财讯11月13日电，康希诺(688185)11月13日公告，公司开发的吸入用肺结核疫苗(5型腺病毒载体) (简称"吸入用结核病加强疫苗")近日于印度尼西亚启动I期临床试验，并完成Ⅰ期临床首例受试者入组。 ...